San Diego, United States
Autobahn Therapeutics, Inc., founded in 2017, is carving a niche in the Central Nervous System (CNS) disorder landscape, with a passionate mantra: "Restoring hope for people affected by CNS disorders." The mission is to transform the treatment paradigm through advanced CNS drug development, addressing the high failure rates and lack of innovation prevalent in this sector.
The company's edge lies in its comprehensive strategy combining deep understanding of disease mechanisms, innovative brain-targeted chemistry, and patient-specific approaches. The flagship therapeutic candidate, ABX-002, is a centrally-penetrant thyroid hormone receptor beta (TRβ) agonist, poised as potential adjunctive therapy for major depressive and bipolar disorder depression.
Prepped with a forward-looking pipeline focused on neuropsychiatry, neurodegeneration, and neuroinflammation, Autobahn Therapeutics seeks strategic investments to propel its groundbreaking work in CNS disorder management, promising transformative outcomes beyond existing therapies.
